NR3C1 and breast carcinoma: Recent translational studies indicate that glucocorticoid receptor (GR) activation increases tumour heterogeneity and metastasis formation, suggesting caution in using glucocorticoids along with chemotherapy for breast cancer patients [1,2,3,4].